---
title: "MEL-Steered PharmacoNet: Adapting DL Prescreening to Synthon-Based Docking for Target-Specific Vir"
id: "biorxiv-0-when-dl-based-prescreening-meets-synthon-based-docking-target-adapting"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-0-when-dl-based-prescreening-meets-synthon-based-docking-target-adapting"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# MEL-Steered PharmacoNet: Adapting DL Prescreening to Synthon-Based Docking for Target-Specific Vir
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-0-when-dl-based-prescreening-meets-synthon-based-docking-target-adapting
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The preprint presents a method to adapt a general-purpose deep-learning pharmacophore prescreener, **PharmacoNet**, to individual protein targets using data already produced during V-SYNTHES-style fragment docking. - V-SYNTHES (Virtual SYNthon Hierarchical Enumeration Screening) docks a Minimal Enumeration Library (**MEL**) of fragments to a pocket, then expands top fragments into full ligands for large-scale docking; only a small fraction of similarly well-scoring fragments are expanded under fixed docking budgets. - General prescreeners can reallocate docking budget by scoring full-ligand proxies, but existing tools do not account for **target-specific** pocket preferences. - The authors propose MEL-Steered PharmacoNet, a parameter-efficient adaptation framework that specializes PharmacoNet to a given target through two mechanisms: empirical density-map steering of predicted pharmacophore hotspots, and empirical fine-tuning of interaction-type scoring weights. - The approach leverages fragment-docking signals (which hotspots and interaction types a pocket favors) to adjust PharmacoNet without additional experimental data or full model retraining. - MEL-Steered PharmacoNet was evaluated on three structurally distinct GPCR targets (CB2, GPR91, 5-HT2AR) and yielded substantial gains in enrichment factor at 100 (EF100) compared with a random baseline and with generic PharmacoNet. - Reported EF100 improvements of MEL-Steered PharmacoNet over PharmacoNet were 8.94x for CB2, 6.87x for GPR91, and 1.69x for 5-HT2AR. - The fitted per-target interaction weights provided chemically interpretable interaction profiles that differ from PharmacoNet's generic fixed weights, indicating pocket-specific interaction preferences recoverable from fragment docking. - The method preserves the ultra-fast screening capability of PharmacoNet while improving target-specific performance and makes use only of fragment-docking data already generated in the V-SYNTHES pipeline.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=RcuQXVEx4qM4q0GjfspzMR5FFrOwiZ2X09va10wTEAo-1788567809.0254261-1.2.1.1-Q.9LxmoS5EJ9zxZcUQZzJc6BbJkQCbJFrO2L59XZtpLsYh70lfyZu8Bi4bh3rCce) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # When DL-Based Prescreening Meets Synthon-Based Docking: Target-Adapting PharmacoNet via MEL-Steered Correction [ View ORCID Profile](http://orcid.org/0009-0004-9977-5224)Wenjin Liu, Yongchan Hong, Thomas Ku, Woojin Lee, Emily Nguyen, Ao Xu, Vsevolod Katritch doi: https://doi.org/10.64898/2026.09.02.748684 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Wenjin Liu 1 Univerisity of Southern California; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wenjin%2BLiu%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Liu%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AWenjin%2BLiu%2B) * [ORCID record for Wenjin Liu](http://orcid.org/0009-0004-9977-5224 "Open in new tab") Yongchan Hong 2 University of Southern California * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yongchan%2BHong%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Hong%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AYongchan%2BHong%2B) Thomas Ku 2 University of Southern California * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2BKu%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Ku%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AThomas%2BKu%2B) Woojin Lee 2 University of Southern California * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Woojin%2BLee%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Lee%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AWoojin%2BLee%2B) Emily Nguyen 2 University of Southern California * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Emily%2BNguyen%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Nguyen%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AEmily%2BNguyen%2B) Ao Xu 2 University of Southern California * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ao%2BXu%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Xu%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAo%2BXu%2B) Vsevolod Katritch 2 University of Southern California * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vsevolod%2BKatritch%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Katritch%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AVsevolod%2BKatritch%2B) * For correspondence: katritch@usc.edu * [Abstract](https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5756829/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5756829/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5756829/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5756829/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract As chemical libraries expand into the trillions of molecules, Virtual SYNthon Hierarchical Enumeration Screening (V-SYNTHES) has emerged as a leading strategy for making gigascale virtual screening computationally tractable. In V-SYNTHES, a Minimal Enumeration Library (MEL) of chemical fragments is docked against a target first, and only the top-scoring fragments are expanded into full ligands for large-scale docking. However, among the large number of comparably well-docked fragments, only a small fraction can be expanded under a fixed docking budget, leaving most similarly promising fragments unexplored. General-purpose prescreening tools can be adopted to address this constraint, reallocating the same docking budget across a larger pool of fragments' enumerated full ligands by their proxy score. However, such tools are applied without accounting for target-specific pocket environments. One such method, PharmacoNet, predicts interaction hotspots from a protein structure and ranks candidates via graph matching against a fixed set of interaction-type weights. We recognize that V-SYNTHES's initial fragment-docking step, ordinarily used only for selection of best fragments for expansion, already reveals which of these hotspots and interaction types a given pocket actually favors, and we can recover this signal to fine-tune PharmacoNet accordingly. We introduce MEL-Steered PharmacoNet, a parameter-efficient adaptation framework that specializes PharmacoNet to a given target through two composable mechanisms: (i) empirical density-map steering of predicted pharmacophore hotspots, and (ii) empirical fine-tuning of interaction-type scoring weights. Across three structurally distinct GPCR targets (CB2, GPR91, 5-HT2AR), MEL-Steered PharmacoNet achieves substantial enrichment factor (EF100) gains over a random baseline, and improves EF100 over PharmacoNet by 8.94x, 6.87x, and 1.69x, respectively. The fitted per-target weights further reveal distinct, chemically interpretable interaction profiles that PharmacoNet's generic fixed weights fail to capture. These results show that fragment-docking data already generated by the standard V-SYNTHES pipeline can adapt a general-purpose pharmacophore prescreening method to an individual target, significantly improving its performance while retaining its ultra-fast screening ability, with no additional experimental data or model retraining. ### Competing Interest Statement The authors have declared no competing interest. ## Funder Information Declared NVIDIA Academic Grant Program Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.09.02.749020v1 "Lens species genome assemblies reveal evolutionarily fragile chromosomes associated with pericentric inversions")[Next ](https://www.biorxiv.org/content/10.64898/2026.09.02.749039v1 "Was the extinct Spectacled Cormorant part of the North Pacific kelp-associated fauna?") Posted September 04, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.09.02.748684v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/09/04/2026.09.02.748684.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) When DL-Based Prescreening Meets Synthon-Based Docking: Target-Adapting PharmacoNet via MEL-Steered Correction Wenjin Liu, Yongchan Hong, Thomas Ku, Woojin Lee, Emily Nguyen, Ao Xu, Vsevolod Katritch bioRxiv 2026.09.02.748684; doi: https://doi.org/10.64898/2026.09.02.748684 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.02.748684v1%26text%3DWhen%2520DL-Based%2520Prescreening%2520Meets%2520Synthon-Based%2520Docking%253A%2520Target-Adapting%2520PharmacoNet%2520via%2520MEL-Steered%2520Correction "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.02.748684v1%26t%3DWhen%2520DL-Based%2520Prescreening%2520Meets%2520Synthon-Based%2520Docking%253A%2520Target-Adapting%2520PharmacoNet%2520via%2520MEL-Steered%2520Correction "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.02.748684v1%26title%3DWhen%2520DL-Based%2520Prescreening%2520Meets%2520Synthon-Based%2520Docking%253A%2520Target-Adapting%2520PharmacoNet%2520via%2520MEL-Steered%2520Correction%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.02.748684v1%26title%3DWhen%2520DL-Based%2520Prescreening%2520Meets%2520Synthon-Based%2520Docking%253A%2520Target-Adapting%2520PharmacoNet%2520via%2520MEL-Steered%2520Correction "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation Tools") [ Get QR code](https://connect.biorxiv.org/qr/2026.09.02.748684) * [Tweet Wid
## Related Clinical Research

- [AA147 and Metabolically Activated Proteostasis Regulators Suppress CD4+ TH17 Differentiation](https://medichelpline.com/clinical-feed/biorxiv-0-metabolically-activated-proteostasis-regulators-reduce-differentiation-of-cd4.md)
- [Chitosan-based hydrogels for intranasal drug delivery in brain disease treatment](https://medichelpline.com/clinical-feed/pubmed-42537824.md) (DOI: 10.1016/j.ijpharm.2026.127259)
- [Centrally Acting Medications and Chronic Pain in Former American Football Players: Study Overview](https://medichelpline.com/clinical-feed/pubmed-42664488.md) (DOI: 10.1212/WNL.0000000000218475)
- [AI-Enhanced Virtual Screening Identifies Selective Small-Molecule Ligands of SV2C](https://medichelpline.com/clinical-feed/biorxiv-15-discovery-of-selective-small-molecule-ligands-of-sv2c-by-ai-enhanced-virtual.md)
- [Which interventions affect biological aging? Epigenetic study finds diet, exercise, and some drugs](https://medichelpline.com/clinical-feed/medical-news-today-0-what-can-and-can-t-slow-down-aging-new-study-offers-clues.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.